Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer

Trim24在乳腺中的特异性表达建立了人类化生性乳腺癌的小鼠模型

阅读:5
作者:Vrutant V Shah # ,Aundrietta D Duncan # ,Shiming Jiang # ,Sabrina A Stratton ,Kendra L Allton ,Clinton Yam ,Abhinav Jain ,Patrick M Krause ,Yue Lu ,Shirong Cai ,Yizheng Tu ,Xinhui Zhou ,Xiaomei Zhang ,Yan Jiang ,Christopher L Carroll ,Zhijun Kang ,Bin Liu ,Jianjun Shen ,Mihai Gagea ,Sebastian M Manu ,Lei Huo ,Michael Gilcrease ,Reid T Powell ,Lei Guo ,Clifford Stephan ,Peter J Davies ,Jan Parker-Thornburg ,Guillermina Lozano ,Richard R Behringer ,Helen Piwnica-Worms ,Jeffrey T Chang ,Stacy L Moulder ,Michelle Craig Barton

Abstract

Conditional overexpression of histone reader Tripartite motif containing protein 24 (TRIM24) in mouse mammary epithelia (Trim24COE) drives spontaneous development of mammary carcinosarcoma tumors, lacking ER, PR and HER2. Human carcinosarcomas or metaplastic breast cancers (MpBC) are a rare, chemorefractory subclass of triple-negative breast cancers (TNBC). Comparison of Trim24COE metaplastic carcinosarcoma morphology, TRIM24 protein levels and a derived Trim24COE gene signature reveals strong correlation with human MpBC tumors and MpBC patient-derived xenograft (PDX) models. Global and single-cell tumor profiling reveal Met as a direct oncogenic target of TRIM24, leading to aberrant PI3K/mTOR activation. Here, we find that pharmacological inhibition of these pathways in primary Trim24COE tumor cells and TRIM24-PROTAC treatment of MpBC TNBC PDX tumorspheres decreased cellular viability, suggesting potential in therapeutically targeting TRIM24 and its regulated pathways in TRIM24-expressing TNBC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。